Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
October 23 2023 - 9:15AM
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of novel treatments for patients suffering
from serious hematologic diseases, announced today that Joanne
Bryce, Chief Financial Officer, plans to depart the company. Disc
has initiated a search to fill the position. To ensure an orderly
transition, Ms. Bryce plans to remain with the company and oversee
her current responsibilities until a successor has been identified.
“On behalf of the Board and the entire Disc team, I want to
thank Joanne for her financial leadership and commitment to the
company. Joanne has been at Disc since its inception and under her
tenure, established our corporate operations, oversaw our
transition to a publicly traded company, and strengthened our
balance sheet over multiple financings,” said John Quisel, J.D.,
Ph.D., President and Chief Executive Officer of Disc. “It is
through her contributions that we can enter the next chapter of
growth and plan for late-stage development from a position of
financial strength. Joanne will be missed by all of us as a valued
colleague and friend, and we wish her all the best.”
“It has been a privilege to be a part of the Disc story and to
see the company grow from a concept on a whiteboard to where it is
today. I’m immensely proud to have worked with this team and am
inspired by their hard-work, talent and tireless dedication to
patients,” said Ms. Bryce. “My time with Disc has been both
professionally and personally fulfilling, but with the company on
firm footing and preparing to embark on the next phase of its
journey, it is a good time for me to pursue other endeavors and
ensure a smooth transition.”
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage
biopharmaceutical company committed to discovering, developing, and
commercializing novel treatments for patients who suffer from
serious hematologic diseases. We are building a portfolio of
innovative, potentially first-in-class therapeutic candidates that
aim to address a wide spectrum of hematologic diseases by targeting
fundamental biological pathways of red blood cell biology,
specifically heme biosynthesis and iron homeostasis. For more
information, please visit www.discmedicine.com.
Disc Cautionary Statement Regarding Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, express or implied statements
regarding the expected departure timeline, search outcome and
transition of Disc’s chief financial officer position and the
Company’s expectations regarding its future growth, plans for
late-stage development and its financial strength. The use of words
such as, but not limited to, “believe,” “expect,” “estimate,”
“project,” “intend,” “future,” “potential,” “continue,” “may,”
“might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could”
or the negative of these terms and other similar words or
expressions that are intended to identify forward-looking
statements.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on Disc’s
current beliefs, expectations and assumptions regarding the future
of Disc’s business, future plans and strategies, clinical results
and other future conditions. New risks and uncertainties may emerge
from time to time, and it is not possible to predict all risks and
uncertainties. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking
statements. Disc may not actually achieve the plans, intentions or
expectations disclosed in these forward-looking statements, and
investors should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements as a result of a number of material
risks and uncertainties including but not limited to Disc’s ability
to timely identify a successor to the chief financial officer
position; Disc’s expectations regarding future growth; the adequacy
of Disc’s capital to support its future operations; and the other
risks and uncertainties described in the “Risk Factors” section of
our Annual Report on Form 10-K for the year ended December 31,
2022, Quarterly Reports on Form 10-Q for the quarters ended March
31, 2023 and June 30, 2023, and other documents filed by Disc from
time to time with the SEC, as well as discussions of potential
risks, uncertainties, and other important factors in Disc’s
subsequent filings with the SEC. Any forward-looking statement
speaks only as of the date on which it was made. None of Disc, nor
its affiliates, advisors or representatives, undertake any
obligation to publicly update or revise any forward-looking
statement, whether as result of new information, future events or
otherwise, except as required by law.
Media Contact
Peg RusconiVerge Scientific
Communicationsprusconi@vergescientific.com
Investor Relations Contact
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Jun 2024 to Jul 2024
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Jul 2023 to Jul 2024